ArticlePediatric blood & cancer2015

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Malcolm A Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.